IL-DURAVANT
22.2.2021 13:02:06 CET | Business Wire | Press release
Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the food processing, packaging and material handling sectors, announced the acquisition of Votech GS B.V. (“Votech”), a leading manufacturer of bag filling machines, palletizer machines, stretch hood machines and pallet transport systems headquartered in Reusel, The Netherlands. Votech will join forces with Fischbein International, a Duravant Operating Company, to serve their global customer base.
The combination of Votech’s expertise in bag management and palletizing and Fischbein’s portfolio of bag sealing and sewing equipment creates a complementary fit between the two companies.
“There is a very complementary relationship between our two organizations,” said Olivier Hancotte, VP and General Manager of Fischbein. “We’re thrilled to work closely with the Votech team to create a broader product offering for both companies’ customers. Fischbein and Votech equipment will both be available through the Fischbein global sales team.”
This partnership brings together two global engineered equipment leaders and extends Duravant’s ability to serve customers and partners in over 190 countries worldwide across multiple sectors including agriculture, industrials, fruit and vegetables, ingredients, pet food and more.
“We’re excited to be a part of the Duravant group of world-class brands and automation solutions,” said Rolf Michiels, Director of Project Sales. “Aligning with the Fischbein team to better serve our customers through a united and collaborative strategy is an exciting prospect for us. Duravant’s lifecycle management via the company’s SupportPro services also gives our customers broader access to value-added solutions that will help their operations achieve their productivity and efficiency goals.”
The Votech brand of packaging machinery has been a competitive force in filling and bag management for over a decade. Votech’s deep engineering and development capabilities allow for the custom design of complete automated solutions from the filling of a bag, to the internal pallet transport to the warehouse. Recognized for superior engineering, package control and local field service support, Votech has proven success delivering packaging solutions for free-flowing and powders applications.
“Our partnership with Duravant opens the path for Votech’s geographic expansion and growth in Europe, the Middle-East, Africa and North America,” adds Pierre Dierckx, Director of Operations. “We’re thrilled to also collaborate with nVenia, Duravant’s US-based operating company serving customers across a wide array of industrial end markets and consumer packaged goods.” The Votech solution set for powders applications is highly complementary with the nVenia product range across primary, secondary and end-of-line packaging.
About Duravant
Headquartered in Downers Grove, IL, Duravant is a global engineered equipment company with manufacturing, sales and service facilities throughout North America, Europe and Asia. Through their portfolio of operating companies, Duravant delivers trusted end-to-end process solutions for customers and partners through engineering and integration expertise, project management and operational excellence. With worldwide sales distribution and service networks, they provide immediate and lifetime aftermarket support to all the markets they serve in the food processing, packaging and material handling sectors. Duravant’s market-leading brands are synonymous with innovation, durability and reliability. For more information, visit www.duravant.com .
About Votech
Headquartered in Reusel, The Netherlands, Votech specializes in developing bag filling and palletizer machines, stretch hood machines and transport systems. The Votech brand has been recognized for providing complete packaging lines from the filling of a bag, through to the internal pallet transport to the warehouse. The entire Votech equipment portfolio is available through Fischbein, a Duravant Company. For more information, visit www.votechbv.co.uk .
About Fischbein
Fischbein designs and manufactures bag packaging equipment and complete systems. For over 100 years, Fischbein has been the leader in sewing and sealing systems by delivering highly engineered, robust and dependable solutions. Serving customers worldwide in agriculture, animal feed, seed, pet food, chemical, mineral, milling, food, building material, medical and pharmaceutical industries, Fischbein has a full range of sealing, filling, weighing, handling, and palletizing equipment that is sold and serviced in more than 190 countries. Fischbein is a Duravant Company. For more information, visit www.fischbein.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005061/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
